| アブストラクト | Statin use has been advocated to prevent atheromatous complications in lupus patients and may be widely prescribed for these patients in future. Statin-induced lupus has also been described, though the risk is not confirmed. The goal of this study was to detect a safety signal regarding statin-induced lupus. We conducted a case/non-case study in the French PharmacoVigilance Database from January 2000 until December 2010. Cases were drug-induced lupus reports. Non-cases were all reports of other adverse drug reactions (ADRs). Exposure to statins at the time of ADR was screened in each report. Among 235,147 ADR reports, 232 were drug-induced lupus. Exposure to statins was present in 17 (7.3%) cases and in 10,601 (4.7%) non-cases. Reporting odds ratio (ROR) for statin exposure associated with lupus erythematosus was 1.67 (95% confidence interval 1.02-2.74). The ROR was > 1 for each statin but fluvastatin. This pharmacoepidemiological study suggests a link between statin exposure and lupus induction. The benefit-to-risk ratio of statin therapy in lupus patients should be evaluated through randomized controlled trials. |
|---|
| ジャーナル名 | Lupus |
|---|
| 投稿日 | 2012/2/16 |
|---|
| 投稿者 | Moulis, G; Bene, J; Sommet, A; Sailler, L; Lapeyre-Mestre, M; Montastruc, J-L |
|---|
| 組織名 | CHU Toulouse, Service de Medecine Interne, Toulouse, F-31059, France.;guillaume.moulis@univ-tlse3.fr |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/22333565/ |
|---|
